iTeos Therapeutics
ITOS
ITOS was delisted on the 28th of August, 2025.
137 hedge funds and large institutions have $396M invested in iTeos Therapeutics in 2023 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 48 increasing their positions, 39 reducing their positions, and 36 closing their positions.
23% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 39
1.81% more ownership
Funds ownership: 99.18% → 100.99% (+1.8%)
2% more capital invested
Capital invested by funds: $389M → $396M (+$7.2M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
5% less funds holding
Funds holding: 144 → 137 (-7)
14% less first-time investments, than exits
New positions opened: 31 | Existing positions closed: 36
86% less call options, than puts
Call options by funds: $2.04M | Put options by funds: $14.1M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$19.8M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
+$11.1M |
| 3 |
Renaissance Technologies
New York
|
+$3.02M |
| 4 |
Citigroup
New York
|
+$2.56M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.91M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$10.2M |
| 2 |
BlackRock
New York
|
-$7.82M |
| 3 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$5.6M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
-$5.48M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$3.2M |
ITOS Hedge Fund Activity: Q4 2023 in Review
137 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in iTeos Therapeutics (ITOS) for Q4 2023, worth a combined $396M — up 1.9% from $389M a quarter earlier.
Sellers outnumbered buyers: 36 funds closed out of ITOS and 31 opened new positions — a net loss of 5 holders — while 39 trimmed existing stakes and 48 added.
The largest buyer was Morgan Stanley, adding an estimated $19.8M. The largest seller was State Street, cutting an estimated $10.2M.
- 137 institutional investors held iTeos Therapeutics (ITOS) as of Q4 2023, down from 144 in Q3 2023.
- Funds reported $396M of iTeos Therapeutics stock for Q4 2023, up 1.9% quarter-over-quarter.
- 31 funds opened new iTeos Therapeutics positions in Q4 2023 and 36 closed out, a net change of -5 holders.
- The largest iTeos Therapeutics buyer in Q4 2023 was Morgan Stanley, an estimated $19.8M added.
- The largest iTeos Therapeutics seller in Q4 2023 was State Street, an estimated $10.2M sold.
Based on aggregated 13F filings for Q4 2023.